AKTS
Aktis Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.05
+1.50%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 9.4M | 6.5M | 1.5M | — | — |
| Cost of Revenue | 1.5M | — | — | — | — |
| Gross Profit | 7.9M | 6.5M | 1.5M | — | — |
| Operating Expenses | |||||
| R&D Expense | 74.4M | 67.5M | 41.0M | 25.9M | 14.3M |
| SG&A Expense | 17.8M | 12.6M | 11.3M | 7.7M | 5.1M |
| General & Admin Expense | 6.5M | 12.6M | 11.3M | 7.7M | 5.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 263.0K | 1.1M | 1.3M | 1.2M | 356.0K |
| Total Operating Expenses | 92.5M | 81.2M | 53.5M | 34.8M | 19.8M |
| Cost and Expenses | 94.0M | 81.2M | 53.5M | 34.8M | 19.8M |
| Operating Income (EBIT) | (84.6M) | (74.7M) | (52.0M) | (34.8M) | (19.8M) |
| Non-Operating | |||||
| Interest Income | 15.0M | 11.0M | 8.1M | 5.4M | 1.6M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 15.0M | 11.0M | 8.1M | 5.4M | 1.6M |
| Other Non-Op Income/Expense | 15.0M | 11.0M | 8.1M | 6.2M | 1.8M |
| Non-Operating Income (excl Interest) | (10.2M) | (11.0M) | (8.1M) | (6.2M) | (1.8M) |
| EBT (Pre-Tax Income) | (69.7M) | (63.7M) | (44.0M) | (28.6M) | (17.9M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (69.7M) | (63.7M) | (44.0M) | (28.6M) | (17.9M) |
| Earnings from Cont. Ops | (69.7M) | (63.7M) | (44.0M) | (28.6M) | (17.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (69.7M) | (63.7M) | (44.0M) | (28.6M) | (17.9M) |
| Per Share | |||||
| Basic EPS | ($1.28) | ($1.19) | ($1.26) | ($0.82) | ($0.51) |
| Diluted EPS | ($1.28) | ($1.19) | ($1.26) | ($0.82) | ($0.51) |
| Revenue Per Share | $0.17 | $0.12 | $0.04 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 55.3M | 52.5M | 34.9M | 34.9M | 34.9M |
| Diluted Shares Outstanding | 55.3M | 52.5M | 34.9M | 34.9M | 34.9M |
| Profitability Metrics | |||||
| EBITDA | (71.8M) | (61.4M) | (42.4M) | (27.4M) | (17.5M) |
| D&A | 2.7M | 2.3M | 1.6M | 1.2M | 445.0K |
| EBIT | (74.4M) | (63.7M) | (44.0M) | (28.6M) | (17.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026